Underwritten Demand

The unified health insurance scheme — Dhamani — is usually read as an access-and-equity story. Read instead as a market mechanism, it is a demand-creation instrument. Mandatory cover converts healthcare that was previously deferred, informal, or paid out of pocket into contracted, billable, direct-pay demand routed through licensed private providers. Where a private operator once faced an uncertain and discretionary customer, it now faces a regulated obligation to insure, a defined minimum package, and a claims rail that settles centrally.

Two details sharpen the picture. The market being fed is already sizeable and growing on its own momentum — Oman’s total insurance premiums reached OMR 551.8 million in 2025, up 8.9 percent on the year, with health the second-largest line at 21.7 percent of premiums and analysts naming mandatory health cover as the sector’s growth driver. And supervision now sits with the Financial Services Authority, the successor body to the former Capital Market Authority that issued the scheme’s founding rules — a small point of currency that a careful reader will check.

Yet the baseline remains overwhelmingly public. Oman’s health system is still financed predominantly by the state, with public expenditure accounting for roughly four-fifths of total health spending in recent national accounts. This matters because Dhamani does not create a private market from zero; it reallocates part of an already-funded national health demand into insured, billable private channels.

A regulated demand floor would matter less if the underlying need were soft or fashion-driven. It is neither. Oman’s population carries one of the heavier non-communicable disease loads in the region, and the official picture points to demand that compounds rather than fades.

The granular risk-factor detail comes from the 2017 STEPS survey, and a new national NCD survey entered field collection in 2025 — so the surveillance is being refreshed rather than left to age. The burden carries an economic weight to match: some estimates place the annual cost of non-communicable disease at around US$1 billion once lost productivity is included. The direction is not in dispute: a young population is aging into chronic disease, and the demand this creates is recurring by nature — diagnostics, long-term management, pharmaceuticals, devices — not the one-off episodic care that prestige facilities are built to bill.

A significant share of the highest-value care Omanis need is currently delivered offshore. The Ministry of Health’s own Department of Treatment Abroad data, analysed in a 2025 population-level study, quantifies a pattern long known anecdotally but rarely evidenced.

The clinical categories matter for where capital should look: these are complex, specialised pathways — transplantation, paediatric sub-specialties, oncology, advanced neurology — not primary care. This is demand that already exists, is already funded, and is simply being fulfilled in the wrong country.

Health is not among the eight sectors a national investment vehicle names as priorities. But that framing mistakes a label for a boundary. Health is not a sector sitting outside those eight — it is a demand engine running through three of them.

Reframed this way, health stops being a sector the mandate skips and becomes a cross-cutting theme the mandate already funds — one that happens to carry a demand profile more certain than most.

Here the analysis turns from opportunity to risk — specifically, the risk of deploying capital into the right sector but the wrong layer of it. Across health systems at Oman’s stage of development, capital and institutional attention tend to gravitate toward prestige tertiary infrastructure: large, visible, monument-scale facilities. The pull is understandable. It is also, on the evidence assembled above, poorly aligned with where risk-adjusted returns actually sit.

The demand curve traced through sections two and three is dominated by chronic-disease management, diagnostics, prevention, and defined specialist pathways — layers that recur, compound, and absorb comparatively little capital per unit of return. Prestige tertiary capacity, by contrast, is capital-intensive, slower to fill, and priced on prestige as much as throughput. The mismatch is not that tertiary infrastructure has no place; it is that the instinctive allocation over-weights it relative to the layers the population’s own disease profile is generating.

For a vehicle writing tickets in the OMR 5–100 million range and taking equity stakes up to a defined ceiling, the thesis translates into a recognisable contour of opportunity — described here as shape, not as a deal list, and with each requiring the independent feasibility validation such decisions properly demand.

The common thread is that each sits on the demand curve the policy has legislated and the epidemiology has guaranteed — and each maps to a sector the mandate already recognises.